Larimar Therapeutics Upsized $100M Public Offering

Larimar Therapeutics, a clinical-stage biotechnology company, announced the pricing of an upsized underwritten public offering of 20,000,000 shares of its common stock at $5.00 per share, expecting to raise $100 million in gross proceeds. The offering also includes a 30-day option for underwriters to purchase an additional 3,000,000 shares. The proceeds will be used to support the development of nomlabofusp, a potential treatment for Friedreich's ataxia, and for general corporate purposes. JPMorgan Chase===J. P. Morgan and Guggenheim Partners are serving as joint bookrunning managers, with LifeSci Capital, William Blair, Citizens Financial Group===Citizens Capital Markets, and Jones Company also involved in the offering. The offering is expected to close around February 27, 2026, subject to customary closing conditions.